secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2026-08-05T21:27:14+00:00
Accession:  0001104659-26-091280
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience prices upsized $300M public offering of common stock at $96/share
--------------------------------------------------------------------------------

- Offering of 3,125,000 shares at $96.00 per share; underwriters' option for 468,750 additional shares exercised in full.
- Net proceeds expected to be approximately $327.1 million after underwriting discounts and expenses.
- Offering upsized from originally proposed $250 million to $300 million; expected to close August 6, 2026.
- Proceeds to fund R&D, manufacturing capacity expansion, product offerings, and working capital.
- Joint book-running managers: Goldman Sachs, William Blair, Leerink Partners, Guggenheim Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000110465926091280/0001104659-26-091280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000110465926091280/tm2622018d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer